NCT01083589View on ClinicalTrials.gov

Imatinib Mesylate and Docetaxel in Non-Small Cell Lung Cancer (NSCLC)

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

October 31, 2007

Study Completion Date

July 31, 2011

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Imatinib Mesylate

Oral 400 mg daily

DRUG

Docetaxel

60 mg/m2 over 1 hour intravenous infusion repeated every 21 days.

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER